清达颗粒对低中危1级高血压患者的影响:随机对照双盲临床试验的研究方案
本研究为随机、多中心、双盲、非劣效性临床试验,拟从13家医院招募552例低中危1级高血压患者,随机分为清达颗粒组(n=276,服用缬沙坦胶囊模拟剂和清达颗粒)或对照组(n=276,服用缬沙坦胶囊和清达颗粒模拟剂)。治疗期4周,治疗后随访4周。主要结局为治疗后收缩压和舒张压的下降值。
要点
- 清达颗粒组服用缬沙坦胶囊模拟剂和清达颗粒,对照组服用缬沙坦胶囊和清达颗粒模拟剂。
- 治疗期4周,治疗后随访4周,主要结局为治疗后收缩压和舒张压下降值。
- 次要结局包括随访结束时血压下降值、血压正常化百分比、汉密尔顿焦虑量表及中医证候评分、高血压激素水平。
核心结论
- 本研究将为清达颗粒治疗低中危1级高血压的临床疗效和安全性提供初步证据。
研究设计与样本
- 研究设计为随机、多中心、双盲、非劣效性临床试验。
- 拟从13家医院招募552例低中危1级高血压患者,随机分为清达颗粒组(n=276)和对照组(n=276)。
- 清达颗粒组服用缬沙坦胶囊模拟剂和清达颗粒,对照组服用缬沙坦胶囊和清达颗粒模拟剂。
- 治疗期4周,治疗后随访4周。
关键数值与推荐
- 主要结局为治疗后收缩压和舒张压的下降值。
- 次要结局包括随访结束时舒张压和收缩压的下降值、治疗结束和随访结束时血压正常化的参与者百分比、汉密尔顿焦虑量表和中医证候评分、治疗结束和随访结束时高血压激素水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous pre-clinical studies showed that Qingda granule (QDG) was effective in treating hypertension. This study aims to evaluate the efficacy and safety of QDG in reducing blood pressure among patients with grade 1 hypertension at low-medium risk. METHODS: The study is designed as a randomized, multi-center, double-blinded, non-inferiority clinical trial. Five hundred fifty-two patients with grade 1 hypertension at low-medium risk from 13 hospitals will be recruited and randomly assigned to the QDG group (n = 276, treated with valsartan capsule simulation agent and QDG) or control group (n = 276, treated with valsartan capsule and QDG simulation agent). The treatment period will be 4 weeks and the follow-up period will last 4 weeks after treatment. Primary outcome will be a decreased value of systolic blood pressure and diastolic blood pressure after treatment. And second outcome will include the decreased value of diastolic blood pressure and systolic blood pressure at the end of follow-up, the percentage of participants achieving normal blood pressure at the end of treatment and follow-up, the Hamilton Anxiety Scale and TCM syndrome scores at the end of treatment and follow-up, and levels of hypertensive hormones at end of treatment and follow-up. DISCUSSION: This study will provide initial evidence regarding the clinical efficacy and safety of QDG in treating grade 1 hypertension at low-medium risk. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000033890 . Registered on 15 June 2020.
引用
- Long LZ, Chu JF, Qu H, et al. Effects of Qingda granule on patients with grade 1 hypertension at low-medium risk: study protocol for a randomized, controlled, double-blind clinical trial. Trials. 2023. PMID: 36588157. doi:10.1186/s13063-022-07006-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。